VERTEX PHARMACEUTICALS INC / MA Quarterly Operating Income (Loss) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly/annual Operating Income (Loss) history and growth rate from Q1 2010 to Q3 2024.
  • Vertex Pharmaceuticals Inc / Ma Operating Income (Loss) for the quarter ending September 30, 2024 was $1.12B, a 7.53% increase year-over-year.
  • Vertex Pharmaceuticals Inc / Ma Operating Income (Loss) for the twelve months ending September 30, 2024 was -$270M, a 107% decline year-over-year.
  • Vertex Pharmaceuticals Inc / Ma annual Operating Income (Loss) for 2023 was $3.83B, a 11% decline from 2022.
  • Vertex Pharmaceuticals Inc / Ma annual Operating Income (Loss) for 2022 was $4.31B, a 54.8% increase from 2021.
  • Vertex Pharmaceuticals Inc / Ma annual Operating Income (Loss) for 2021 was $2.78B, a 2.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$270M $1.12B +$78.2M +7.53% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$349M -$3.51B -$4.54B -442% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $4.19B $1.14B +$361M +46.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $3.83B $989M -$45M -4.35% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $3.88B $1.04B -$88.6M -7.86% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $3.97B $1.03B -$79.9M -7.22% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 $4.05B $779M -$262M -25.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $4.31B $1.03B +$156M +17.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $4.15B $1.13B +$72.2M +6.85% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $4.08B $1.11B +$1.14B Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $2.94B $1.04B +$153M +17.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $2.78B $878M +$132M +17.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $2.65B $1.05B +$382M +56.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $2.27B -$37.9M -$756M -105% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $3.02B $888M +$168M +23.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $2.86B $746M +$194M +35.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $2.66B $672M +$573M +577% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $2.09B $718M +$448M +166% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $1.64B $720M +$443M +160% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $1.2B $551M +$424M +332% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 $774M $99.3M -$106M -51.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 $880M $270M +$97.1M +56.2% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 $783M $277M +$148M +115% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 $635M $128M +$1.99M +1.58% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $633M $206M +$532M Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 $101M $173M +$120M +228% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 -$18.7M $129M -$142M -52.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 $123M $126M +$86.1M +217% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-13
Q3 2017 $37.1M -$326M -$307M -1641% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-13
Q2 2017 $344M $52.7M +$49.4M +1472% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-13
Q1 2017 $295M $271M +$285M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-13
Q4 2016 $9.94M $39.6M +$93.3M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 -$83.4M -$18.7M +$51.3M +73.3% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 -$135M $3.35M +$175M Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 -$309M -$14.3M +$158M +91.7% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 -$467M -$53.7M +$99.9M +65% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 -$567M -$70M +$72.2M +50.8% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 -$639M -$171M +$9.38M +5.19% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 -$648M -$172M +$44.1M +20.4% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
Q4 2014 -$692M -$154M -$143M -1394% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-16
Q3 2014 -$549M -$142M -$18.6M -15.1% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-16
Q2 2014 -$530M -$181M -$134M -284% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-16
Q1 2014 -$397M -$216M +$213M +49.7% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-16
Q4 2013 -$610M -$10.3M +$67.2M +86.7% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-13
Q3 2013 -$677M -$124M -$122M -11437% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-13
Q2 2013 -$555M -$47M -$36.3M -337% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-13
Q1 2013 -$518M -$429M -$521M -568% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-13
Q4 2012 $2.33M -$77.5M -$301M -135% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-11
Q3 2012 $304M -$1.07M -$217M -100% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-11
Q2 2012 $520M -$10.8M +$155M +93.5% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-11
Q1 2012 $365M $91.6M +$252M Jan 1, 2012 Mar 31, 2012 10-K 2014-02-11
Q4 2011 $114M $224M +$391M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 -$277M $216M +$415M Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 -$692M -$166M +$3.68M +2.17% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 -$696M -$160M +$383K +0.24% Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
Q4 2010 -$696M -$167M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-22
Q3 2010 -$200M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-22
Q2 2010 -$170M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-22
Q1 2010 -$160M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.